ZNF610

Across TCGA pan-cancer cohorts, ZNF610 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ZNF610’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZNF610 RNA is repressed in tumor relative to normal tissue. In most cancer types ZNF610 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, BRCA, and CHOL are the cancer types where ZNF610 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF610 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.552	<.001	8	view →
BRCA	All	II,III,IV	+0.397	<.001	6	view →
CHOL	All	All	+1.400	<.001	4	view →
BLCA	Female	IV	+1.316	.003	4	view →
KICH	All	All	−0.541	.003	4	view →
LIHC	All	All	+0.304	.001	4	view →
THCA	Male	IV	−0.583	.016	3	view →
LUSC	Male	All	−0.348	.017	3	view →
PRAD	All	All	+0.589	<.001	2	view →
LUAD	Male	All	+0.413	.031	2	view →
COAD	Female	All	−0.376	.029	2	view →
ESCA	Female	All	−0.839	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ZNF610–KIRC

Open the KIRC breakdown →